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KPC-type carbapenem-hydrolyzing enzymes have been
increasingly reported among Enterobacteriaceae worldwide and
have been a major determinant of carbapenem resistance in this
family, particularly in Klebsiella pneumoniae isolates.1 Only
recently, KPC enzymes have been described in K. pneumoniae
isolates in Brazil.2 Nonetheless, following this ﬁrst report in the
northeastern region, other cases have been described in two cities
in the southeastern region.3,4 In fact, Pavez et al.4 have shown that
these isolates have been present in this region since at least 2005.
In this communication, we describe another case of KPC-2-
producing K. pneumoniae occurring in southern Brazil.
In October 2005, an isolate was recovered from the urine of a
patient admitted to the intensive care unit of a hospital in
Floriano´polis, the capital of Santa Catarina, the second southern-
most state of Brazil. We identiﬁed the isolate using API20E
(bioMe´rieux, Marcy l’Etoile, France). The minimum inhibitory
concentrations (MICs) for antibiotics were determined by Etest (AB
Biodisk, Solna, Sweden), except for polymyxin B, which was
determined by agar dilution, and were as follows: amikacin
>256 mg/l, ampicillin/sulbactam>256 mg/l, aztreonam>256 mg/
l, ceftriaxone >32 mg/l, ceftazidime >256 mg/l, cefepime
>256 mg/l, piperacillin/tazobactam >256 mg/l, ertapenem
>32 mg/l, imipenem = 4 mg/l, meropenem = 4 mg/l, tigecycli-
ne = 2 mg/l, and polymyxin B = 1 mg/l. The MIC of ciproﬂoxacin
was not determined, but it was resistant by disk diffusion method.
The modiﬁed Hodge test5 was positive, as well as PCR for KPC-2-
type gene, performed as described elsewhere.6 The ampliﬁed
product was sequenced with the automated ﬂuorescent dye
terminator sequencing system (Applied Biosystems, Foster City,
CA, USA) and a homology search was done using the BLAST
program available from the DNA Data Bank of Japan (DDBJ).
This is the ﬁrst reported case of KPC-2-producing K. pneumoniae
in southern Brazil. So far, only episodic cases have been reported in
our country. Nonetheless, it has now been shown that these
bacteria are present in Brazilian cities at distances of more than
3000 km apart. Moreover, we have also shown that KPC-2-
producing K. pneumoniae have been present in our country since
at least 2005, only nine years following its ﬁrst detection in the USA
in 1996.1 It is known from previous reports that more than one
clone of KPC-2-producing K. pneumoniae have already been
identiﬁed,2–4 but whether one or more strains have been
disseminated across these cities warrants further investigation.
The presence of KPC-2 in many Brazilian regions is of
paramount importance considering the continental dimensions1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.07.004of this country. This report raises concerns that these isolates may
become endemic or epidemic in our country. Considering the
previous cases of multidrug-resistant organisms that have become
endemic, such as SPM-1-producing Pseudomonas aeruginosa,7 or
epidemic, such as OXA-23-producing Acinetobacter baumannii,8
associated with our recent ﬁnding of clonally related KPC-2-
producing Enterobacter cloacae isolates in different cities of
southern Brazil,9 our concern is justiﬁable. Heightened awareness
of the Brazilian clinical microbiology laboratories for the detection
of KPC-producing K. pneumoniae is urgently required in order to
avoid a large-scale dissemination of this multidrug-resistant
organism.
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